drugset / Trial / NCT03951415
Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
Phase 2
Unknown
55 enrolled
Leiden University Medical Center
Amsterdam University Medical Center · collabAstraZeneca · collabErasmus Medical Center · collabMaastricht University Medical Center · collabRadboud University Medical Center · collabThe Netherlands Cancer Institute · collabUMC Utrecht · collabUniversity Medical Center Groningen · collab
NaSingle-groupOpen-labelTreatment
Summary
The DOMEC trial is designed as a Dutch Gynecological Oncology Group (DGOG), prospective, multi-center, phase II study for 55 patients with advanced (recurrent, refractory or metastatic) endometrial cancer or carcinosarcoma of the uterus to investigate the efficacy of the combination therapy of olaparib tablets and durvalumab IV.
Timeline
- Start
- 2019-07-08
- Primary completion
- 2021-08-01
- Completion
- 2021-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Olaparib | Small molecule | 300 mg | Oral |